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AbsTrACT
Objective The aim of the meta- analysis was to 
determine the association of obesity and heart failure 
(hF) and the cardiac impact of intentional weight loss 
following bariatric surgery on cardiac structure and 
myocardial function in obese subjects.
Methods MeDline, embase and Web of science 
were searched up to 3 april 2018. studies reporting 
association and prognostic impact of obesity in hF and 
the impact of intentional weight loss following bariatric 
surgery on cardiac structure and myocardial function in 
obesity were included in the meta- analysis.
results 4959 citations were reviewed. after exclusions, 
29 studies were analysed. a ’J curve’ relationship was 
observed between body mass index (BMi) and risk of 
hF with maximum risk in the morbidly obese (1.73 
(95% ci 1.30 to 2.31), p<0.001, n=11). although 
’obesity paradox’ was observed for all- cause mortality, 
the overweight group was associated with lower 
cardiovascular (cV) mortality (Or=0.86 (95% ci 0.79 to 
0.94), n=11) with no significant differences across other 
BMi groups. intentional weight loss induced by bariatric 
surgery in obese patients (n=9) without established hF, 
atrial fibrillation or known coronary artery disease, was 
associated with a reduction in left ventricular mass index 
(p<0.0001), improvement in left ventricular diastolic 
function (p≤0.0001) and a reduction in left atrial size 
(p=0.02).
Conclusions Despite the increased risk of hF 
with obesity, an ’obesity paradox’ is observed 
for all- cause mortality. however, the nadir for cV 
mortality is observed in the overweight group. 
importantly, intentional weight loss was associated 
with improvement in indices of cardiac structure and 
myocardial function in obese patients.
Trial registration number aPP 74412.
InTrOduCTIOn
Obesity is a modern- day epidemic affecting more 
than one- third of the population worldwide.1 
Similarly, heart failure (HF) is a major public 
health problem with an estimated lifetime risk of 
one in five. Obesity is considered to contribute 
to the increasing incidence of all subgroups of 
HF.2 However, there have been variable reports 
on the impact of obesity on HF prognosis.3 
Though wasting in terminal HF patients has been 
associated with poor prognosis, a recent bariatric 
surgery study has shown that intentional weight 
loss in obese patients is associated with reduced 
risk of incident HF.4 5 The present ACCF/AHA 
society guidelines appreciate that obesity is a risk 
factor for HF but do not have firm recommenda-
tions on weight management in HF.6 
Therefore, a potential beneficial impact of 
intentional weight loss in obese patients continues 
to be a issue of conjecture but worth investi-
gating given the benefit observed in other patient 
populations such as atrial fibrillation (AF).7 8 
The purpose of this systematic review and meta- 
analysis is to evaluate the relationship between 
obesity and the incidence of HF and its impact on 
prognosis in HF in the general population and to 
explore the impact of intentional weight loss in 
obese individuals on indices of cardiac structure 
and function by bariatric surgery.
MeTHOds
This systematic review complies with the Meta- 
analysis of Observational Studies in the Epide-
miology group and Preferred Reporting Items 
for Systematic Review and Meta- Analysis state-
ments. The meta- analysis was registered with 
PROSPERO International register for systematic 
reviews (APP 74412).
search strategy
The English scientific literature was searched 
using PubMed, Embase and Web of Science 
between the period 1 January 1950 to 3 April 
2018 with the assistance of an experienced 
librarian. The following keywords were used 
‘Obesity’, ‘abdominal obesity’, ‘Diabetic Obesity’, 
‘Metabolic Syndrome X’, ‘Morbid Obesity’, body 
mass index’, ‘obesity hypoventilation syndrome’, 
‘cardiorenal syndrome’, ‘congestive heart failure’, 
‘heart failure with preserved ejection fraction’, 
‘diastolic dysfunction’ ‘heart ventricle failure’, 
‘bariatric surgery’, ‘intentional weight loss’, ‘left 
ventricle’, ‘left ventricular hypertrophy’, ‘cardiac 
hypertrophy’, ‘natriuretic peptide’, ‘BNP’ and 
‘NT- BNP’. The details are provided in online 
supplementary 1 The retrieved references were 
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Inclusion and exclusion criteria
The inclusion criteria were: (1) original articles describing the 
association of obesity and HF; (2) obesity categories defined 
according to standard guidelines: underweight, normal BMI, 
overweight and obese defined as BMI <18.5 kg/m2, 18.5–
24.9 kg/m2, 25.0–29.9 kg/m2 and ≥30 kg/m2, respectively. 
Severe obesity and morbid obesity were defined as BMI 
>35 kg/m2 and >40 kg/m2, respectively; (3) HF defined as per 
standard definitions such as ICD-9 or ICD-10, Framingham 
Heart Study Criteria or European Society of Cardiology (ESC) 
guideline definition. The exclusion criteria were: (1) acute 
decompensated HF; (2) studies reporting on RV dysfunction 
only; (3) BMI categories not defined as per standard guide-
lines; (4) conference abstracts, editorials, reviews, letters and 
case reports; (5) small sample size (incidence <5000 patients; 
prognosis <500 patients and intentional weight loss achieved 
through bariatric surgery <50 patients); (6) HF prognosis 
studies of 1 year or less in follow- up duration; (7) intentional 
weight loss studies that recruited patients with HF in selected 
population with coronary artery disease or AF only; and (8) 
intentional weight loss studies with inadequate echocardio-
graphic data. The exclusion of intentional weight loss studies 
that included patients with AF and coronary artery disease 
was deemed necessary to provide a representative cohort of 
obese subjects without cardiac conditions that are impacted by 
intentional weight loss. Where multiple studies described the 
same population (substudies and follow- up studies), the study 
with the most comprehensive data was included.
study selection and data extraction
The study selection and data extraction were performed by authors 
(RM and MS), using the predefined inclusion and exclusion 
criteria. Although review articles were excluded, their reference 
lists were examined for potential relevant publications. During 
data extraction, information was collected on the study design, 
follow- up time, outcome measures, method of assessing outcomes, 
inclusion/exclusion criteria and results. Where available, the 
maximally adjusted risk ratios were extracted and pooled across 
studies. The data were reviewed by two authors independently and 
disagreements resolved by consensus. The methodological qualities 
of the included studies were assessed using the Newcastle- Ottawa 
Scale. The outcomes of the analysis were defined as: (1) incidence 
of chronic HF across various BMI categories in general population; 
(2) effect of BMI on cardiovascular (CV) and all- cause mortality in 
chronic HF in general population; and (3) impact of intentional 
weight loss achieved via bariatric surgery in obese individuals on 
cardiac structure and function.
statistical analysis
Continuous variables are presented as the mean or median and 
categorical variables as n (%). Separate meta- analyses were 
performed for: (1) incidence of chronic HF across various 
BMI categories; (2) effect of BMI on prognosis in chronic 
HF; and (3) impact of intentional weight loss on adverse 
cardiac remodelling and indices of myocardial function in 
obese individuals. Where meta- analysis was not feasible due 
to small patient or study numbers, raw results were tabulated. 
A random effects model, using the DerSimonian & Laird 
method, was used to pool data across studies. Meta- analysis 
was performed using Review Manager V.5.3. Two meta- 
analytic effects size types were used for the data analyses, 
namely: standardised mean difference (SMD) and ORs. SMD 
was used for reporting association with change in indices of 
myocardial function as some studies reported indexed values, 
scaled to body size, rather than absolute values. Back transfor-
mation was not always possible. The I2 statistic was used as a 
measure of variability in observed effect estimates attributable 
to heterogeneity between the studies.
resulTs
search and synthesis of the literature
The online search of PubMed, Embase and Web of Science 
from 1 January 1950 to 3 April 2018 yielded 4959 citations. 
Hand searching of references of reviews did not yield addi-
tional citations. Of these, 4794 citations were excluded on 
primary review as they did not meet the inclusion criteria. One 
hundred and sixty- five citations were identified for secondary 
review. After removal of studies with sample size less than 
defined (in exclusion criteria), reviews and non- relevant arti-
cles (n=98), BMI categories not defined according to WHO 
guidelines,8 inadequate data for research questions (n=29) 
and redundant studies (n=1), 29 studies were included in the 
final analysis. Of these, 9 studies reported on the association 
of obesity with HF,2 9–15 11 studies reported on the impact of 
BMI on prognosis in chronic HF16–26 and 9 studies reported 
on the impact of intentional weight loss following bariatric 
surgery on cardiac structure and function.26–34 Figure 1 
provides the Consolidated Standards of Reporting Trials flow 
diagram for the data search.
Obesity and incidence of HF
Nine studies consisting of 375 056 patients with mean 
age 53±8 years and follow- up of 12±6 years were anal-
ysed.2 9–14 35 36 Two of the studies used ESC guideline criteria 
for HF diagnosis,13 36 three of the studies used the Framingham 
Heart Study criteria for diagnosis2 11 12 and the remaining four 
studies used ICD-9 and ICD-10 criteria for diagnosis.9 10 14 35 
Three studies were in diabetic cohorts. Online supplementary 
2 provides the study design and the baseline characteristics 
of patients in studies assessing the incidence of HF in obesity. 
Insufficient data on left ventricular ejection fraction (LVEF) 
was reported in these studies. For each categorical BMI 
group, the incidence of HF was 0.99, 0.34, 0.59, 1.05 and 
2.79 cases per 100 person- years for the underweight, normal, 
overweight, obese and morbid obese groups, respectively. The 
risk of incident HF (reference group: normal BMI) across 
BMI categories was 1.22 (95% CI 0.95 to 1.58, p=0.12)), 
1.11 (95% CI 0.97 to 1.27, p=0.13), 1.62 (95% CI 1.32 to 
1.99, p<0.001) and 1.73 (95% CI 1.30 to 2.31, p<0.001) for 
underweight, overweight, obese and severely obese individ-
uals, respectively (Figures 2,3A). There was evidence of signif-
icant heterogeneity among all comparisons other than that for 
underweight versus normal BMI.
Impact of obesity on CV and all-cause mortality in HF
Eleven studies, consisting of 41 019 patients with mean age 
67±4 years and follow- up of 4.8±3.4 years, were anal-
ysed.16–26 The HRs for CV mortality (reference group: normal 
BMI) across BMI categories were 1.20 (95% CI 0.61 to 2.39, 
n=2 studies,16 23 p=0.6), 0.86 (95% CI 0.79 to 0.94); n=3 
studies16 21 23 p=0.001) and 0.97 (95% CI 0.72 to 1.33, 
n=4 studies,16 21 23 26 p=0.87) for underweight, overweight 
and obese individuals, respectively (Figures 4B,5). The CV 
mortality was lower in the overweight group relative to 
normal BMI individuals with absence of significant heteroge-
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Figure 1 Search criteria and flow diagram of the literature selection process. BMI, body mass index; HF, heart failure.
significantly different in the other groups analysed. There was 
substantial heterogeneity observed in these groups (I2 ≥79%, 
p≤0.03). Insufficient data were available to perform a meta- 
analysis on CV mortality in patients considered severely obese.
Table 1 provides the study design and the baseline charac-
teristics of patients in studies assessing the impact of obesity 
on all- cause mortality in patients with HF. The risk for all- 
cause mortality was significantly higher in the underweight 
group with progressive decline in mortality with increase in 
BMI from underweight to severely obese categories. The HRs 
for all- cause mortality in HF in underweight, overweight, 
obese and morbidly obese categories were 1.40 (95% CI 1.25 
to 1.57, n=4 studies,16 19 20 p<0.001), 0.88 (95% CI 0.79 
to 0.98, n=10 studies,16–25 p=0.02), 0.80 (95% CI 0.69 to 
0.91, n=10 studies,16–25 p<0.001) and 0.80 (95% CI 0.77 
to 0.83, n=2 studies,20 21 p<0.001), respectively. There was 
evidence of statistical heterogeneity among included studies 
in the overweight and obese analyses (p<0.001, I2 >90%). 
Figure 5 shows the forest plots demonstrating the relationship 
of all- cause mortality to BMI.
effect of intentional weight loss on cardiac structure and 
function in obesity
Nine bariatric surgery studies reported intentional weight loss 
with a mean reduction in weight of 39.4 kg (n=8; 95% CI 
−45.5 kg to −33.4 kg) and reduction in BMI by 13.6 kg/
m2 (n=9; 95% CI −15.6 kg/m2 to −11.6kg/m2) over a mean 
follow up of 18.1±15.2 months.26–34 The weight loss surgeries 
used were gastric bypass,26 27 29–31 33 biliopancreatic diversion 
with duodenal switch,32 gastric sleeve,26 30 33 34 and vertical 
banded gastroplasty.33 One study did not specify the type of 
bariatric surgery used.28 Intentional weight loss resulted in 
reduced left ventricular mass index (SMD −0.49, 95% CI 
−0.73 to −0.26; p<0.0001), improvement in diastolic func-
tion (E/A- SMD 0.65, 95% CI 0.38 to 0.91; p<0.0001) and 
reduced left atrial size (SMD −0.39, 95% CI −0.72 to −0.07; 
p=0.02). There was also a non- significant improvement 
in LVEF (SMD 0.43, 95% CI 0.00 to 0.86; p=0.05). One 
study compared two different surgical approaches and did not 
report any difference in outcome. Figure 6 shows the impact 




































61Mahajan r, et al. Heart 2020;106:58–68. doi:10.1136/heartjnl-2019-314770
Heart failure and cardiomyopathies
Figure 2 Increased incidence of HF with obesity. Panels A, B, C and D: HF incidence in underweight, overweight, obese and morbid obese patients 
with heart failure (HF), respectively.
study quality and the assessment of risk of bias
All included studies were representative of the relevant cohort 
with adequate sample size. There was low risk of detection and 
information biases in all studies. Online supplementary tables 
3A, 2B,Cprovides the modified Newcastle Ottawa Score for the 
included studies.
dIsCussIOn
The relationship of obesity with HF is complex with several studies 
signalling a paradoxical relationship for mortality. The current 
meta- analysis highlights the increasing risk of HF across the cate-
gories of BMI. Despite the higher incidence of HF with obesity, 
in the presence of established HF, obesity was associated with a 
paradoxical decline in all- cause mortality. A U- shaped relationship 
curve was observed between CV mortality and BMI; the over-
weight cohort experiencing least CV mortality. Importantly, inten-
tional weight loss by bariatric surgery in obese patients resulted in 
improvement in indices of cardiac structure and myocardial func-
tion. The impact of weight loss interventions on clinical outcomes 




































62 Mahajan r, et al. Heart 2020;106:58–68. doi:10.1136/heartjnl-2019-314770
Heart failure and cardiomyopathies
Figure 3 Panel A: J shaped relationship of obesity and HF incidence. Panel B: U shaped relationship of obesity and cardiovascular mortality in HF 
with nadir shifted to overweight group.
J-curve relationship between obesity and risk of HF
The current meta- analysis suggests the presence of a ‘J- curve’ 
relationship between obesity and the risk of incident HF. 
While there was non- significant 22% and 11% greater risk of 
incident HF among underweight and overweight participants, 
respectively, the obese and morbidly obese participants had 
62% and 73% greater risk of developing HF.
The mechanisms of HF in obesity are multifactorial. Both 
experimental and clinical studies have demonstrated that 
obesity leads to increases in cardiac output and in left heart 
filling pressures, with subsequent left ventricular hyper-
trophy and cardiac remodelling resulting in diastolic dysfunc-
tion.37 38 Although overt systolic dysfunction is uncommon 
in the absence of other CV disease, subclinical myocardial 
dysfunction characterised by decreased systolic mitral annular 
velocities and reduced longitudinal strain are well described 
in obesity studies.39 Obesity is also associated with clustering 
of incident CV risk factors that contribute to the development 
of ischaemic heart disease, which alone represents a signifi-
cant aetiological burden of HF. Furthermore, the metabolic 
syndrome and obstructive sleep apnoea that are frequently 
present in obese individuals may also contribute to adverse 
left ventricular loading, dilatation and hypertrophy, pulmo-
nary hypertension and subsequently biventricular failure.37 39 
In addition to abnormal loading conditions, epicardial adipose 
tissue has been shown to infiltrate the underlying cardiac 
muscle and produce profibrotic and proinflammatory cyto-
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Figure 4 Obesity and cardiovascular mortality. Panel A, B and C: Cardiovascular mortality in underweight, overweight and obese heart failure 
patients respectively. BMI, body mass index; CV, cardiovascular; HF, heart failure.
develop over several years leading to a steep increase in risk 
of HF after 10 years of severe obesity.41
Obesity paradox in HF: myth or reality
The obesity paradox has been a long- standing controversy 
with studies demonstrating lower mortality in obese patients 
with HF. Horwich et al3 were the first to report the obesity 
paradox in HF. Further studies have reported best outcomes 
in the overweight (BMI 25–29.9) or obese (BMI 30–34.9) 
categories with increasing mortality seen at the extreme ends 
of the scale.3 21 23 42 The current meta- analysis confirms the 
paradoxical decline in all- cause mortality with increasing 
obesity and demonstrates a U- curve for CV mortality with 
best outcomes in the overweight group.
The obesity paradox has been attributed to many factors, 
but the exact mechanisms remain unclear (Box 1). Obese 
patients may experience greater functional impairment and 
present early in the course of the disease.16 Similarly, older 
age, lower use of beta- blocker and ACE inhibitors and cardiac 
cachexia have been reported in low BMI groups.4 The obesity 
paradox has been shown to be eliminated, though inconsis-
tently, when adjustments are made for variables such as age, 
left ventricular function19 and cardiorespiratory reserve.43 
Criticism of the obesity paradox in HF includes the observa-
tion that much of the data which supports this paradox arises 
from post hoc analysis of clinical trials designed for different 
purposes, retrospective studies or the analysis of registries 
arousing concerns of statistical validity and possible unmea-
sured confounding induced by selection bias. A lead time bias 
in diagnosis of HF in the obese and a lower specificity of a 
HF diagnosis in obese individuals may also impact upon prog-
nostic data. Obese patients with HF possess different clinical 
and epidemiological profiles compared with normal weight 
patients with HF, which may impact upon mortality. Thus, 
comparing HF outcomes on BMI may not account for differ-
ences in age, aetiology of HF, LVEF, blood pressure, presence 
of anaemia, diabetes mellitus, renal function and nutritional 
status where differences are present when comparing obese 
versus non- obese individuals.44
Intentional weight loss in obese HF cohort
The observation of the obesity paradox in HF has raised scep-
ticism on any potential therapeutic benefit from intentional 
weight loss in obese patients with HF. However, a recent 
large Swedish registry has provided robust data on the bene-
ficial effects of intentional weight loss in the prevention of 
HF development in obese patients.5 This study demonstrated 
a graded decrease in the risk of incident HF with weight loss. 
A weight loss of 10 kg was associated with a 23% lower risk 
of developing HF. In concurrence with this study, the current 
meta- analysis showed that intentional weight loss in obesity 
resulted in improvement in diastolic function and reduction in 
LV mass as well as left atrial size. This reverse and favourable 
cardiac remodelling may potentially avert the future devel-
opment of HF in obesity. The weight loss was achieved with 
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Figure 5 Obesity and all- cause mortality. Panel A, B, C and D: All- cause mortality in underweight, overweight, obese and morbidly- obese heart 
failure patients respectively.
Notably, there is a striking lack of significant clinical studies 
on the direct role of intentional weight loss in established 
HF. However, the potential benefit of intentional weight 
loss as a therapeutic intervention in HF is suggested by a 
few bariatric surgical studies in patients with HF. First, Vest 
et al reported retrospective data from 42 patients with left 
ventricular systolic dysfunction (LVEF <50%) who underwent 
bariatric surgery with a mean follow- up period of 23 months. 
Bariatric surgery resulted in a reduction in BMI of 11 kg/m2 
and a mean LVEF improvement of 5.1% with no significant 
cardiac adverse events.45 Similarly, improvement in LVEF has 
been demonstrated in other small case series in obese patients 
with HF.46 47 In addition, reduction in HF hospitalisation by 
intentional weight loss by bariatric surgery has been demon-
strated in a recently published self- controlled series of 524 
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Table 1 Baseline characteristics of patients in studies assessing the impact of obesity on all- cause mortality in heart failure




male) Age (years) lVeF (%) nYHA
HF aetiology 
(% ischaemic) HTn (%) dM (%)
Curtis et al16 RCT 3 75.4 64±11 31±13 I–IV 63.2 47.1 28.4



































































































































































































BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; MOB, morbid obesity; N, normal BMI; NR, not reported; NYHA, New York Heart Association; OB, 
obese; OW, overweight; RCT, randomised controlled trial; UW, underweight.
loss achieved via non- surgical approaches (via caloric restric-
tion and/or aerobic exercise training) has also been found to be 
beneficial in improving peak oxygen uptake, in patients with 
HF- PEF.49 Similarly, a small study of a 6- month dietary- led 
interventional weight loss programme in 34 obese chronic HF 
patients whereby a modest weight loss of 3 kg was achieved 
resulted in improvements in functional assessments as well as 
LVEF.50 Further substantial clinical data are required to deter-
mine whether weight loss achieved via differing surgical or 
non- surgical approaches results in differing haemodynamic 
effects and clinical outcomes in the HF population.
Clinical implications
Intentional weight loss has been previously shown to be 
beneficial in obese patients with other CV disorders such as 
AF.7 8 The current meta- analysis shows that obesity is asso-
ciated with HF, and intentional weight loss leads to favour-
able cardiac remodelling in the obese. It also demonstrates the 
least CV mortality in HF in the overweight group. Hence, this 
meta- analysis provides theoretical data with regard to poten-
tial prognostic benefit from intentional weight loss in obese 
patients with HF. This information may be crucial in designing 
studies to evaluate the role of intentional weight loss in such 
a cohort.
limitations
Although BMI is the most common anthropometric measure 
of adiposity, it does not accurately distinguish between body 
fat and lean mass, and the relation between BMI and body 
fat varies with age, gender and ethnicity. Furthermore, under-
nutrition may be present in patients classified as obese on 
the basis of BMI. Despite the limitations, the BMI was the 
most suitable measure to conduct this meta- analysis. Several 
studies did not report the aetiology of HF, which is a crucial 
factor determining prognosis. In addition, the studies did not 
provide differentiation between HF with reduced ejection 
fraction and HF preserved ejection fraction. Furthermore, 
there were insufficient studies to conduct an analysis for CV 
mortality in morbidly obese patients with HF. There are also 
too few studies to draw definite conclusions regarding weight 
management in HF. Although the bariatric surgery studies 
provided evidence for improvement in a number of cardiac 
indices, there was a paucity of information on improvement in 
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Figure 6 Intentional weight loss leads to favourable adaptive cardiac remodelling. LVEF, left ventricular ejection fraction.
the measurement of a left atrial diameter from the parasternal 
long- axis imaging was used in the bariatric surgery studies. 
This measurement, while regularly performed in routine echo-
cardiography, is prone to angulation and foreshortening. It has 
been essentially superseded by an indexed volumetric assess-
ment (left atrial volume, indexed to body surface area), in 
echocardiographic laboratories.
COnClusIOn
Obesity is associated with an increased risk of developing HF. 
Despite the elevated risk, a paradoxical decline in all- cause 
mortality is observed. Similarly, a U- shaped curve exists for 
CV mortality with best outcome evident in the overweight 
group. Intentional weight reduction results in improvement in 
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box 1 Obesity paradox and heart failure
support of the obesity paradox in heart failure
 ► High volume clinical registry data indicating a lower mortality 
in overweight and mildly obese individuals with heart failure.
 ► Cardiac cachexia a poor prognostic feature in heart failure.
 ► Potential protective effects of: tumour necrosis factor- alpha 
(secreted from adipose tissue).
 ► Increased tolerability of disease modifying and prognostic 
pharmacotherapies in the obese.
Controversial aspects and possible explanations obesity 
paradox in heart failure
 ► Lower specificity of heart failure diagnosis in the obese.
 ► Lead time bias in diagnosis of heart failure in the obese.
 ► Different clinical and epidemiological profile of heart failure 
in the obese.
 ► Statistical validity of large study data, predominantly with 
body mass index.
 ► Inherent limitations of body mass index alone as a measure 
of obesity.
free of HF. Given the burgeoning population incidence of HF, 
adequately powered and appropriately designed studies to 
assess the effects of intentional weight loss in obese patients 
with HF are urgently required.
Key messages
What is already known on this subject?
 ► The management of obesity in heart failure is controversial.
What might this study add?
 ► The meta- analysis confirms the increased risk of HF with 
obesity and presence of an ‘obesity paradox’ for all- cause 
mortality. Intentional weight loss improves indices of cardiac 
function.
How might this impact on clinical practice?
 ► Collider stratification bias, lead time bias and different 
baseline characteristics may explain the obesity paradox. 
There are no data to suggest detrimental effect of intentional 
weight loss in obese patients with heart failure. Further 
studies are required to evaluate the role of intentional weight 
loss in obese patients with heart failure.
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